威高血净今日启动A股IPO申购 血液净化龙头登陆资本市场

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. has officially launched its A-share IPO subscription, with an issue price of 26.50 yuan per share, corresponding to a price-to-earnings ratio of 24.82 times [1] Group 1: Issuance Overview - The issuance method includes strategic placement, offline issuance, and online issuance [2] - The total issuance volume is 41,139,407 shares, with a post-issuance total share capital of 411 million shares [2] - The online subscription code is 732014, with subscription times set for May 8, 2025, from 9:30 to 11:30 and 13:00 to 15:00 [2] Group 2: Financial Performance - The company has maintained steady growth over the past three years, achieving operating revenues of 3.426 billion yuan, 3.532 billion yuan, and 3.604 billion yuan for 2022, 2023, and 2024 respectively [2] - The net profit attributable to the parent company for the same years was 315 million yuan, 442 million yuan, and 449 million yuan [2] - In 2023, the company held a market share of 32.5% in blood dialysis devices and 31.8% in blood dialysis tubing, ranking first in the industry [2] Group 3: Industry Leadership - As one of the few companies to break through technical barriers in the blood purification field, the company has established a full product line covering blood dialysis devices, blood dialysis machines, and peritoneal dialysis solutions [3] - The company's self-developed blood dialysis device products have reached internationally leading performance indicators [3] - The sales network covers all 31 provincial-level administrative regions and over 6,000 medical institutions, including more than 1,000 tertiary hospitals [3] Group 4: Fundraising Projects Focused on Core Business - The raised funds will focus on intelligent production construction, the establishment of a dialysis device production base in Ganzhou, research and development center construction, and digital information technology platform projects [4] - The completion of these projects will enhance the company's automation production capacity and research efficiency, solidifying its industry-leading position [4] Group 5: Future Development Layout - The company aims to leverage this listing opportunity to deepen its "R&D + market" dual-drive strategy, improve talent incentive mechanisms, and optimize production capacity layout [5] - The company plans to actively explore emerging markets such as Indonesia, aiming to build a globally influential national brand in blood purification [5]